# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

> **NCT05555823** · PHASE1 · COMPLETED · sponsor: **Atriva Therapeutics GmbH** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ATR-002
- **DRUG:** Placebo
- **DRUG:** Repaglinide
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT05555823
- **Lead sponsor:** Atriva Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-23
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-07-20
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555823, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05555823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*